ABSTRACT
BACKGROUND: In recent years, the incidence of inflammatory bowel disease is yearly increasing, and there are no effective treatment plans. Mesenchymal stem cells have achieved good outcomes in the treatment of immune-related diseases such as systemic lupus erythematosus, myocardial infarction and graft-versus-host disease. Numerous studies have shown that mesenchymal stem cells have their unique advantages in thetreatment of inflammatory bowel disease. Therefore, increasing concern has been placed on the treatment of inflammatory bowel disease by mesenchymal stem cells. OBJECTIVE: To summarize the existing research on the treatment of inflammatory bowel disease by mesenchymal stem cells, and to discuss its application and safety. METHODS: “Mesenchymal stem cells, inflammatory bowel disease, pathogenesis, treatment” were used as keywords to search CNKI, WanFang and PubMed databases for relevant literatures in the past 20 years both in Chinese and English. Finally, 62 papers were selected for review. RESULTS AND CONCLUSION: Mesenchymal stem cells have the abilities of self-renewal, tissue migration and pluripotency, as well as strong immunomodulatory effects. They not only show satisfying therapeutic effects in systemic lupus erythematosus, myocardial infarction, graft-versus-host disease and other immune-related diseases, but also have promising prospects in inflammatory bowel disease. However, little is reported in clinical studies, and there are still many problems, such as safety, encountered in the treatment of inflammatory bowel disease with mesenchymal stem cells.
ABSTRACT
As one of the most effective and commonly used analgesic methods during labor and delivery,epidural analgesia has been widely accepted in terms of its safety.Neurological complications following childbirth,which are most related to pregnancy and childbirth factors rather than labor analgesia,has not been well studied or recognized in China.Therefore,there are some confusions and misunderstandings of reasons for these neurological complications,and,to a certain extent,have affected the clinical implementation of epidural labor analgesia.This review analyzed the etiology and prognosis of this problem in order to help the clinicians in identifying the risk factors and causes and also to improve clinical awareness,prevention,and management for these conditions.
ABSTRACT
Objective@#To study the effect of oral metformin on the prognosis of patients with gastric cancer.@*Methods@#The clinical data of 364 patients with gastric cancer admitted to the First Affiliated Hospital of Medical College of Shantou University from January 2013 to December 2017 were collected.The patients were divided into metformin group (31 cases), non-metformin group (35 cases) and non-diabetic group (298 cases) according to whether they were diabetes or treated with metformin.The mortality and survival of the three groups were compared.@*Results@#The mortality rate was 12.9%(4/31) in the metformin group, 74.3%(26/35) in the non-metformin group, 52.0%(155/298) in the non-diabetic group, and the mortality rate in the metformin group was lower than that in the other two groups, the differences were statistically significant(χ2=10.081, P=0.001; χ2=7.681, P=0.006), and the metformin group had the lowest mortality rate.There was no statistically significant difference between the non-metformin group and the non-diabetic group (χ2=1.665, P=0.197). The survival time of the metformin group, non-metformin group and non-diabetic group were (29.017±16.254) months, (9.692±10.355) months and (16.748±8.526)months, respectively.The survival time of the metformin group was longer than that of the non-metformin group (t=5.827, P=0.000) and the non-diabetic group (t=6.843, P=0.000), and the survival time of the non-diabetic group was longer than that of the non-metformin group (t=4.523, P=0.000), and the overall survival of patients in the metformin group was prolonged.Clinical staging, treatment of gastric cancer, alcohol consumption and oral metformin treatment were independent factors influencing the prognosis of patients with gastric cancer.@*Conclusion@#Oral metformin can improve the prognosis of patients with gastric cancer and prolong the life of patients.
ABSTRACT
Objective To study the effect of oral metformin on the prognosis of patients with gastric cancer. Methods The clinical data of 364 patients with gastric cancer admitted to the First Affiliated Hospital of Medical College of Shantou University from January 2013 to December 2017 were collected.The patients were divided into metformin group (31 cases),non-metformin group (35 cases) and non-diabetic group (298 cases) according to whether they were diabetes or treated with metformin.The mortality and survival of the three groups were compared. Results The mortality rate was 12.9%(4／31) in the metformin group,74.3%(26／35) in the non -metformin group,52.0%(155／298) in the non-diabetic group,and the mortality rate in the metformin group was lower than that in the other two groups ,the differences were statistically significant (χ2 ＝10.081,P＝0.001;χ2 ＝7.681,P＝0.006),and the metformin group had the lowest mortality rate.There was no statistically significant difference between the non-metformin group and the non-diabetic group (χ2＝1.665,P＝0.197).The survival time of the metformin group, non-metformin group and non-diabetic group were (29.017 ±16.254) months,(9.692 ±10.355) months and (16.748 ± 8.526)months,respectively.The survival time of the metformin group was longer than that of the non-metformin group (t＝5.827,P＝0.000) and the non-diabetic group (t＝6.843,P＝0.000),and the survival time of the non -diabetic group was longer than that of the non -metformin group (t＝4.523,P＝0.000),and the overall survival of patients in the metformin group was prolonged.Clinical staging,treatment of gastric cancer ,alcohol consumption and oral metformin treatment were independent factors influencing the prognosis of patients with gastric cancer .Conclusion Oral metformin can improve the prognosis of patients with gastric cancer and prolong the life of patients .
ABSTRACT
<p><b>OBJECTIVE</b>To study the hypolipidemic active compounds from Crataegus pinnatifida and mechanism of action of those.</p><p><b>METHOD</b>Guided by the inhibitory activity to HMG-CoA reductase, the active compounds were separated and purified with macroporous resin and silica gel.</p><p><b>RESULT</b>Four active compounds were obtained, which were quercetin, hyperoside, rutin and chlorogenic acid, the sum of their inhibitory rate was 50.01%, and the total inhibitory rate of the mixture of four active compounds matched was 79.48%.</p><p><b>CONCLUSION</b>Quercetin and hyperoside were the principle active components inhibiting HMG-CoA reductase in Hawthorn fruit, and there were synergistic action among them.</p>
Subject(s)
Crataegus , Chemistry , Fruit , Chemistry , Hydroxymethylglutaryl CoA Reductases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Pharmacology , Plant Extracts , PharmacologyABSTRACT
<p><b>OBJECTIVE</b>To determine the pharmacokinetics, distribution and mutual transformation of the total alkaloids, jatrorrhizine, coptisine, berberine and palmatine from Coptis chinensis in rats.</p><p><b>METHOD</b>After the total alkaloids and berberine were fed into rats, their contents in plasma, tissues and gastrointestinal tract were determined by reversed-phase HPLC.</p><p><b>RESULT</b>The peak times of berberine in blood were 2.0 h (Cmax 3.7 mg x L(-1)) and 5.0 h Cmax 2.8 mg x L(-1)), respectively. Berberine in rat blood can be transformed into jatrorrhizine. After the rats were fed with the total alkaloids by gavage, the content of berberine was decreased monotonously, while coptisine, palmatine and jatrorrhizine contents were increased gradually in the stomach, it speculated that berberine may be transformed into jatrorrhizine in the stomach. Animal experiments showed that berberine and palmatine were mainly distributed in the lungs of animals, followed by the distribution in the liver, while jatrorrhizine and coptisine was mainly in the liver, then in the lungs.</p><p><b>CONCLUSION</b>Berberine could transform into jatrorrhizine. The mechanism on the appearance of two maximum blood concentration of berberine in blood could be explained with the propulsion of the gastrointestinal tract partly.</p>
Subject(s)
Animals , Female , Male , Rats , Alkaloids , Metabolism , Pharmacokinetics , Biotransformation , Coptis , Chemistry , Drugs, Chinese Herbal , Metabolism , Pharmacokinetics , Random Allocation , Rats, Sprague-Dawley , Tissue DistributionABSTRACT
OBJECTIVE:To evaluate efficacy and safety of caspofungin for non-effect/intolerant to fluconazole in patients with invasive fungal infetion(IFI) in intensive care unit(ICU).METHODS:A retrospective analysis was conducted in 14 IFI patients in ICU who was without effect/intolerant to gluconazole.They were treated with caspofungin in a dose of 70 mg in the first day,and then in a dose 50 mg?d-1 for 3～28 d.RESUITS:Of total 14 cases,2 cases had been diagnosed including 1 case of candidemia albicans and 1 case of pulmonary candidosis glabrata;5 probable cases including 2 cases of pulmonary aspergillus species,2 cases of pulmonary candidosis albicans and 1 cases of pulmonary candidosis parapsilosis;In 7 suspected cases pathogen fungus were not found out.One patient died of respiratory failure at third day of treatment.Clinical efficacy of death case cannot be evaluated.Of total evaluable 13 cases,2 were cured(2/13,15.4%),4 markedly effective cases(4/13,30.8%),2 improved cases(2/13,15.4%) and 5 ineffective cases(5/13,38.5%),the overall effective rate was 46.2%.Caspofungin can be tolerated by all patients during therapy without drug related adverse reaction.CONCLUSION:Caspofungin is certain of efficacy and safety for non-effect/intolerant to fluconazole in IFI patients in ICU,and is the first choice for IFI patients in ICU.